Sunshine Biopharma, Inc. (SBFM)
1.11
-0.06
(-5.13%)
USD |
NASDAQ |
Sep 03, 16:00
1.13
+0.02
(+1.80%)
After-Hours: 20:00
Sunshine Biopharma Enterprise Value : -10.41M for Sept. 3, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 03, 2026 | -10.41M |
| September 02, 2026 | -10.26M |
| September 01, 2026 | -10.36M |
| August 31, 2026 | -10.38M |
| August 28, 2026 | -10.31M |
| August 27, 2026 | -10.02M |
| August 26, 2026 | -10.10M |
| August 25, 2026 | -10.33M |
| August 24, 2026 | -10.29M |
| August 21, 2026 | -10.29M |
| August 20, 2026 | -10.29M |
| August 19, 2026 | -10.26M |
| August 18, 2026 | -10.38M |
| August 17, 2026 | -10.38M |
| August 14, 2026 | -10.31M |
| August 13, 2026 | -10.19M |
| August 12, 2026 | -10.17M |
| August 11, 2026 | -10.12M |
| August 10, 2026 | -10.14M |
| August 07, 2026 | -10.12M |
| August 06, 2026 | -9.713M |
| August 05, 2026 | -9.880M |
| August 04, 2026 | -9.928M |
| August 03, 2026 | -10.26M |
| July 31, 2026 | -10.26M |
| Date | Value |
|---|---|
| July 30, 2026 | -10.12M |
| July 29, 2026 | -10.12M |
| July 28, 2026 | -9.641M |
| July 27, 2026 | -9.403M |
| July 24, 2026 | -9.092M |
| July 23, 2026 | -8.973M |
| July 22, 2026 | -8.734M |
| July 21, 2026 | -8.877M |
| July 20, 2026 | -8.925M |
| July 17, 2026 | -8.758M |
| July 16, 2026 | -8.686M |
| July 15, 2026 | -8.614M |
| July 14, 2026 | -8.471M |
| July 13, 2026 | -8.399M |
| July 10, 2026 | -8.065M |
| July 09, 2026 | -7.946M |
| July 08, 2026 | -7.993M |
| July 07, 2026 | -8.089M |
| July 06, 2026 | -7.850M |
| July 02, 2026 | -8.017M |
| July 01, 2026 | -7.850M |
| June 30, 2026 | -8.041M |
| June 29, 2026 | -5.12M |
| June 26, 2026 | -5.086M |
| June 25, 2026 | -5.105M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.913B |
| Alnylam Pharmaceuticals, Inc. | 35.05B |
| Anika Therapeutics, Inc. | 267.88M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 2.003B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.564M |
| Revenue (Quarterly) | 9.264M |
| Total Expenses (Quarterly) | 10.83M |
| EPS Diluted (Quarterly) | -1.146 |
| Gross Profit Margin (Quarterly) | 25.35% |
| Profit Margin (Quarterly) | -16.88% |
| Earnings Yield | -921.3% |
| Normalized Earnings Yield | -826.62 |